Patents Represented by Attorney, Agent or Law Firm Valeta Gregg
  • Methods of treating inflammatory skin diseases
    Patent number: 6833349
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal. Also disclosed are methods of treating diseases in which plasma leakage and/or vascular permeability occurs, for example, inflammatory skin diseases.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: December 21, 2004
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Yuping Xia, John S. Rudge, George D. Yancopoulos
  • Expressed ligand—vascular intercellular signalling molecule
    Patent number: 6825008
    Abstract: The present invention provides for a modified TIE-2 ligand which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor. The invention further provides for a modified TIE-2 ligand which is a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first. In a specific embodiment, the invention further provides for a chimeric TIE ligand comprising at least a portion of TIE-2 Ligand-1 and a portion of TIE-2 Ligand-2. In addition the present invention provides for isolated nucleic acid molecule encoding the modified TIE-2 ligands described.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: November 30, 2004
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Samuel Davis, George D. Yancopoulos
  • Methods of using cytokine antagonists to treat HIV infection and AIDS
    Patent number: 6811780
    Abstract: The invention is methods of using cytokine antagonists to treat HIV. In particular, the invention is methods of treating HIV using L-4 and IL-13 cytokine antagonists, including cytokine traps and anti-IL-4 or anti-IL-13 antibodies. The invention also includes augmenting the efficacy of HIV vaccination by co-administration of the vaccine with IL-4 and IL-13 cytokine antagonists.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: November 2, 2004
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric S. Furfine, Neil Stahl
  • Use of ciliary neurotrophic factor
    Patent number: 6767894
    Abstract: Compositions and methods for the intranasal or respiratory administration of ciliary neurotrophic factor proteins, especially in the treatment of obesity and gestational or adult onset diabetes.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: July 27, 2004
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Vivien W. Wong, Ellen M. Koehler-Stec, Neil Stahl
  • Modified ciliary neurotrophic factor, method of making and methods of use thereof
    Patent number: 6680291
    Abstract: Modified ciliary neurotrophic factor, methods for production and methods of use, especially in the treatment of Huntington's disease, obesity, and gestational or non insulin-dependent diabetes mellitus.
    Type: Grant
    Filed: December 3, 1999
    Date of Patent: January 20, 2004
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Stanley J. Wiegand, Mark W. Sleeman, Philip D. Lambert
  • Clock gene and methods of use thereof
    Patent number: 6476188
    Abstract: The present invention discloses the identity of the first enzyme that has been demonstrated to be involved in maintaining circadian rhythms. This enzyme, the Drosophila DOUBLETIME protein is also shown to be an ortholog of human casein kinase-1&egr;. In addition, a variant of this enzyme is shown to be cause of the hamster tau mutant phenotype. Thus the present invention also relates to variants of DOUBLETIME, and their nucleic acid and amino acid sequences. The present invention further provides methods of using these variants in drug assays and diagnostics.
    Type: Grant
    Filed: April 20, 2000
    Date of Patent: November 5, 2002
    Assignees: The Rockefeller University, Northwestern University
    Inventors: Michael W. Young, Brian Kloss, Justin Blau, Jeffrey Price, Joseph S. Takahashi, Phillip L. Lowrey
  • Methods for computer-assisted isolation of proteins
    Patent number: 6459994
    Abstract: The present invention is directed to efficient, computer-assisted methods and apparatus for identifying, selecting and characterizing biomolecules in a biological sample. According to the invention, a biological sample is first treated to isolate biomolecules of interest, and a two-dimensional array is then generated by separating the biomolecules present in a complex mixture. The invention provides a computer-generated digital profile representing the identity and relative abundance of a plurality of biomolecules detected in the two-dimensional array, thereby permitting computer-mediated comparison of profiles from multiple biological samples. This automatable technology for screening biological samples and comparing their profiles permits rapid and efficient identification of individual biomolecules whose presence, absence or altered expression is associated with a disease or condition of interest.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: October 1, 2002
    Assignee: Oxford GlycoSciences (UK) Ltd
    Inventors: Rajesh Bhikhu Parekh, James Alexander Bruce, Robin Philp, Lida H. Kimmel, David L. Friedman
  • Identifying compounds inhibiting DC-sign facilitation of HIV into cells
    Patent number: 6391567
    Abstract: The present invention demonstrates that a receptor, named DC-SIGN, is specifically expressed on dendritic cells, and facilitates infection of T lymphocytes with HIV. Assays for identifying compounds that modulate the interaction of DC-SIGN and HIV and/or T cells and macrophage are provided. Compounds so identified are also part of the present invention.
    Type: Grant
    Filed: March 2, 2000
    Date of Patent: May 21, 2002
    Assignee: New York University
    Inventors: Dan R. Littman, Douglas Kwon, Yvette Van Kooyk, Teunis Geijtenbeek
  • Stabilized aqueous peptide solutions
    Patent number: 6384016
    Abstract: Aqueous compositions comprising at least one peptide selected from glucagon, GLP-1, and analogues and derivatives thereof together with a stabilizing and solubilizing amount of at least one detergent, said detergent having at least 2 positive charges, at least 2 negative charges, or a combination of at least one positive charge and at least one negative charge.
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: May 7, 2002
    Assignee: Novo Nordisk A/S
    Inventor: Niels C. Kaarsholm
  • Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
    Patent number: 6316489
    Abstract: This invention relates to (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine D-tartrate, preparation thereof and use as therapeutic agent.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: November 13, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Claus Ulrich Jessen, Petra Christine Lugstein
  • cis3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
    Patent number: 6316494
    Abstract: The present invention relates to therapeutically active compounds of formula I a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.
    Type: Grant
    Filed: October 27, 1997
    Date of Patent: November 13, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Poul Jacobsen, Svend Treppendahl, Paul Stanley Bury, Anders Kanstrup, Lise Brown Christiansen
  • Compounds, their preparation and use
    Patent number: 6300339
    Abstract: The present invention relates to compounds of formula (I) wherein A, B, Q, T, X, Y, Z, R5, R6, R7, R8, Ar, k, m, n and p are as defined in the specification. These compounds are useful in treating or preventing conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: October 9, 2001
    Assignees: Novo Nordisk A/S, Dr. Reddy's Research Foundation
    Inventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
  • Shuffling of heterologous DNA sequences
    Patent number: 6291165
    Abstract: The present invention relates to a new method of shuffling especially heterologous polynucleotide sequences, screening and/or selection of new recombinant proteins resulting therefrom having a desired biological activity, and especially to production and identification of novel proteases exhibiting desired properties.
    Type: Grant
    Filed: March 17, 1998
    Date of Patent: September 18, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Torben Vedel Borchert, Titus Kretzschmar, Joel R. Cherry
  • Treatment of Infertility
    Patent number: 6281013
    Abstract: In an in vitro fertilization method, a woman is treated with a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof for a short period of time and, thereafter, using in vitro oocyte maturation egg or eggs are retrieved from the woman and are maturated using a meiosis activating compound.
    Type: Grant
    Filed: March 20, 2000
    Date of Patent: August 28, 2001
    Assignee: Novo Nordisk A/S
    Inventor: Christian Grøndahl
  • Method of treating gastrointestinal motility disorders
    Patent number: 6281232
    Abstract: The present invention relates to a novel method for treating a mammal suffering from gastrointestinal motility disorders.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 28, 2001
    Assignee: Novo Nordisk A/S
    Inventor: Beverley Greenwood
  • Method of treating gastrointestinal motility disorders
    Patent number: 6281233
    Abstract: The present invention relates to a novel method for treating a mammal suffering from gastrointestinal motility disorders.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 28, 2001
    Assignee: Novo Nordisk A/S
    Inventor: Beverley Greenwood
  • 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
    Patent number: 6277991
    Abstract: The present invention relates to the use of small organic compounds acting as opioid receptor ligands for the treatment of vasomotor disturbances. In particular the present invention relates to the use of triaza-spiro compounds of formula wherein R1, R2, R3, R4, R5, z and n are defined in the specification, for the treatment of migraine, non-insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence and/or vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: August 21, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Rolf Hohlweg, Brett Watson, Christain Thomsen
  • Treatment of type 1 diabetes
    Patent number: 6274549
    Abstract: Insulin analogues which are substantially devoid of hypoglycemic effect can be used for treating of delaying the onset of type 1 diabetes or ameliorating of an early stage thereof in a mammal at risk of developing diabetes.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: August 14, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Dyrberg, Anne Worsaae
  • Compounds, their preparation and use
    Patent number: 6274608
    Abstract: Disclosed are novel compounds of formula I wherein R1, R2, R3, L, X and Y are as defined in the specification. These compounds are useful in the treatment of conditions mediated by nuclear receptors, in particular the Retinoid X Receptor (RXR) and the Peroxisome Proliferator-Activated Receptor (PPAR) families. Such conditions include diabetes and obesity.
    Type: Grant
    Filed: April 18, 2000
    Date of Patent: August 14, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Per Sauerberg, Anthony Murray, Lone Jeppesen, Paul Stanley Bury, Ingrid Pettersson
  • Method of treating gastrointestinal motility disorders
    Patent number: 6271229
    Abstract: The present invention relates to a novel method for treating a mammal suffering from gastrointestinal motility disorders.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 7, 2001
    Assignee: Novo Nordisk A/S
    Inventor: Beverley Greenwood